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  I
n 2004 the Global Fund to Fight 
AIDS, Tuberculosis, and Malaria 
(“Global Fund”) awarded program 
grants to Burma (Myanmar) totaling 
US$98.4 million over ﬁ  ve years—
recognizing the severity of Burma’s 
HIV/AIDS and tuberculosis (TB) 
epidemics, and noting that malaria 
was the leading cause of morbidity 
and mortality, and the leading killer of 
children under ﬁ  ve years old [1]. For 
those individuals working in health in 
Burma, these grants were welcome, 
indeed [2]. 
    In that same year, Burma’s 
authoritarian military regime—the 
State Peace and Development Council 
(SPDC)—was accused of severe and 
ongoing human rights violations, and 
United Nations Secretary General Koﬁ   
Annan appointed a Special Rapportuer 
on Human Rights, signaling a high 
level of concern about the junta’s 
governance. Given these occurrences, 
the Global Fund imposed additional 
safeguards on their Burma grants—
including additional monitoring of 
activities and expenditures—and 
requested and received written 
guarantees from the junta to respect 
the fund’s safeguards and performance-
based grant system.
    On August 18, 2005, the Global 
Fund announced termination of 
the grants, stating that “given new 
restrictions recently imposed by the 
government which contravene earlier 
written assurances it has provided the 
Global Fund, the Global Fund has now 
concluded that the grants cannot be 
implemented in a way that ensures 
effective program implementation” 
[1]. The fund made it clear that the 
decision was due to the SPDC having 
imposed restrictions on access to 
project implementation areas, and 
having added additional procedures to 
the procurement of medical supplies. 
Despite the statement from the Global 
Fund, some individuals involved in 
health within Burma have argued that 
political pressure from the United 
States played a role in the withdrawal. 
    In the same month, the executive 
director of the World Food Programme 
visited Burma and called for a 
relaxation of government controls 
on the procurement and distribution 
of food commodities [3]. The World 
Food Programme reported that one in 
three Burmese children was chronically 
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  Figure 1.   Distribution of Reported Malaria Deaths in Southeast Asia, 2003
      Burma accounts for about 7% of malaria cases reported in Southeast Asia, including India, yet over 
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malnourished or stunted, and that 15% 
of the 2005 population of 53 million 
was food-insecure [3]. In December 
2005, the medical charity Médecins 
Sans Frontières France reported 
that they, too, were withdrawing 
from Burma, and again cited junta 
restrictions on staff travel to project 
areas as the primary cause [4]. And 
in February 2006, the International 
Committee of the Red Cross suspended 
a prisoner-visiting program as a result 
of insistence by junta that the junta 
supervise such visits [5]. 
    In each case, restrictions on 
health and/or humanitarian activity 
have included lengthy delays for 
approval to travel to project sites, 
variously reported as taking up to 
three weeks; the addition of junta 
approved “minders” on all site visits; 
and limits on the time allowed at 
sites. In February 2006, the SPDC 
Ministry of National Planning and 
Economic Development put forward 
guidelines for NGOs, UN agencies, 
and international organizations 
working in Burma [6]. The guidelines 
formalize, reafﬁ  rm, and expand those 
restrictions that led to the Global 
Fund pullout—such as ministry-level 
approval of programs; coordination, 
project implementation, opening 
and registration of ﬁ  eld ofﬁ  ces; 
appointment of staff; internal 
travel; management and equipment 
purchases; and coordination at the 
state, division, and township levels [6].
    The program withdrawals from 
Burma highlight what has become a 
contentious and complex dilemma 
for the international community: how 
best to respond to the health crises 
affecting the people of Burma. While 
some donors have withdrawn from 
Burma, others including the European 
Commission have called for increased 
levels of humanitarian assistance 
[7]. And a number of longstanding 
collaborative groups—such as 
Population Services International, 
which has done condom social 
marketing in Burma since 1996—have 
continued operations in the country 
(http://www.psi.org). The aid dilemma 
has become more compelling as 
Burma’s health and humanitarian 
crises have been increasingly 
recognized as playing important roles 
in South and Southeast Asia [8]. 
  Methods
    We reviewed the recent medical and 
policy literature on Burma, with a focus 
on HIV/AIDS, TB, and malaria. We 
searched the PubMed database using 
MeSH terms “Burma” and “Myanmar.” 
We reviewed all articles from January 
1, 2004, to May 1, 2006, relevant to 
HIV/AIDS, TB, and malaria. We 
reviewed data available on Burma’s 
health expenditures and infrastructure 
and on SPDC policies, and analyzed 
information from a variety of sources 
and informants—attempting, wherever 
possible, to assess the validity of reports. 
Given the range of limitations on the 
availability of information from Burma, 
including restrictions imposed by the 
SPDC on publications and reports, 
we acknowledge that there are likely 
to have been information sources 
that were unavailable to us. We had 
the following objectives: attempt to 
synthesize what is known about HIV/
AIDS, TB, malaria, and other disease 
threats—including avian inﬂ  uenza 
(H5N1 virus) in Burma; assess the 
regional health and security concerns 
associated with these epidemics; and 
suggest policy options that would 
respond to these threats in the context 
of the tightening restrictions imposed 
by the junta. Field investigations 
were conducted by our group and by 
Burmese colleagues in 2005 and 2006, 
which included visits to health facilities 
in Burma and along its borders, as well 
as discussions with health professionals 
inside and outside the country.
  SPDC  Health  Expenditures 
and Policies 
    The SPDC has been cited for its 
markedly low levels of public funding 
for health and education [8]. Public-
sector investment in education and 
health care combined, in Burma, is less 
than US$1 per person, per year—one 
of the lowest levels worldwide [8]. This 
contributed to Burma’s low ranking 
in the World Health Organization 
(WHO) millennium assessment of 
health-care systems—190th out of 191 
nation states [9]. Health and education 
systems receive less than 3% and 10% 
of expenditures, respectively [10,11]. 
Table 1 shows recent disease-speciﬁ  c 
expenditures for SPDC budgets. The 
2003 malaria expenditure ﬁ  gure of 
US$23 million is the largest disease-
speciﬁ  c expenditure reported that 
year by the Burmese government. The 
entire health budget for that year was 
US$18 million in 2003, meaning that 
this malaria ﬁ  gure must be interpreted 
with caution.
    Widespread corruption has 
weakened the health sector [11–14]. 
Disinvestment has also eroded Burma’s 
educational system, a situation that 
continues to worsen as many skilled 
educators and professionals have 
emigrated [15]. Where available in 
Burma, libraries and other educational 
facilities are still inadequate [16,17]. 
Although the junta purports to be 
producing more graduates, decreases 
in medical and nursing education 
standards raise questions about the 
skills of recent graduates (http:⁄⁄www.
myanmar.com/Ministry/health/g09.
htm).
    Burma’s laboratory infrastructure has 
also weakened, both directly as a result 
of disinvestment and indirectly from 
creating a dearth of skilled technical 
personnel [18]. The US Centers for 
Disease Control and Prevention mission 
to Burma is one of the few external 
laboratory assessments available. 
The mission’s assessment was that 
laboratory infrastructure in the public 
sector was markedly underfunded 
and underdeveloped, and in need of 
expansive investment [19].
  Table 1.   SPDC Expenditures for Disease Control, 2003–2005, for Selected Infectious 
Diseases  
Disease Year Expenditures (US$)
Malaria a 2003 23,041,000
HIV/AIDS b 2004 22,000
TB c 2005 312,000
Filariasis d 2004 6,000
  a SPDC total health budget was US$18 million for the same year (2003) [42].
  b Data from National AIDS Control Program.
  c The total reported budget was US$5,200,000, which came mostly from donors; the amount that the SPDC contribution 
to the National TB Program was 6% [18].
  d WHO Biennium Budget ( see http://www.searo.who.int/LinkFiles/
New_Lymphatic_Filariasis_Annual_Report_Myanmar_2004.pdf)
  DOI:  10.1371/journal.pmed.0030393.t001 
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    HIV/AIDS, TB, and Malaria 
in Burma
      HIV/AIDS.   We reported an estimate 
of the scale of Burma’s HIV/AIDS 
epidemic in 2003 using data from the 
national HIV sentinel surveillance 
and a national household survey to 
generate conservative estimates of 
HIV prevalence [2]. We estimated 
a population rate of 3.46% of 
reproductive age adults living with 
HIV in mid-year 2000, with a range 
of 2.72%–4.19% [2]. The Joint UN 
Programme on HIV/AIDS estimated 
a slightly lower prevalence in 2000 
and some 46,000 AIDS-related deaths 
that year—Burma’s national reporting 
system identiﬁ  ed 802 AIDS-related 
deaths [2]. The sentinel surveillance 
was apparently either suspended or not 
reported until March–April 2003, when 
it was again undertaken (Tables 2 and 
3). 
    Table 2 shows the 2003 national HIV 
sentinel surveillance results. Most risk 
groups were sampled only in Rangoon 
and Mandalay. Overall, sample sizes 
were small, making the ranges of 
minimum and maximum prevalence 
(shown as reported by the National 
AIDS Control Programme) quite wide: 
the median HIV prevalence among 
the 2,713 male patients with sexually 
transmitted diseases (STDs) surveyed 
was 6%, giving a minimum of 0% and 
a maximum of 21%. The minimum 
would suggest low HIV prevalence; 
the maximum, the highest in Asia. 
Similarly, the range for pregnant 
women is 0%–7.5% HIV prevalence—
wide enough to make interpretation 
difﬁ  cult. These data suggest that the 
HIV sentinel surveillance is probably 
too limited in scale and scope to 
accurately capture HIV/AIDS in this 
large and diverse country [20].
    Table 3 presents the same 2003 
surveillance data by site; gives 
percentages, not absolute numbers; 
and suggests additional concerns with 
the surveillance system. Sex worker 
rates in the two cities sampled are 
quite divergent, with 11% reported 
prevalence in Rangoon and 55.17% 
in Mandalay. Looking at rates among 
pregnant women from the same two 
cities, we see 2.0% prevalence in 
Rangoon, but strikingly lower HIV 
seropositivity (0.50%) in Mandalay. 
While such an outcome is possible 
given the small samples, it is unlikely. 
Further uncertainty is evidenced 
as women attending an STD clinic 
in Rangoon had higher rates of 
HIV/AIDS than sex workers, while 
the opposite was true in Mandalay. 
Such divergent ﬁ  ndings suggest 
more methodologic and sampling 
differences than true variance in 
rates. The US Centers for Disease 
Control and Prevention mission to 
Burma in 2002 came to the same 
conclusion, advocating for improved 
surveillance methods and laboratory 
upgrades [21]. The Centers for 
Disease Control and Prevention also 
proposed a collaboration to make these 
improvements. This effort did not go 
forward when the junta refused to allow 
for conﬁ  dential voluntary counseling 
and testing [21, 22]. All HIV-positive 
test results continue to be reported to 
the junta.
    Molecular epidemiologic data 
from several groups working both 
within the country and in the 
country’s border regions with India, 
China, and Thailand suggest that 
Burma’s epidemic is characterized 
by marked viral diversity, high rates 
of recombination and circulating 
recombinant forms, and high rates of 
HIV and hepatitis C coinfection among 
injection drug users (IDUs) [22–30]. 
This molecular picture has been linked 
to Burmese heroin-trafﬁ  cking routes, 
and to the very-high-exposure settings 
among IDUs in upper Burma. IDUs 
typically use drugs at tea-stall settings—
where injection equipment is kept on 
the premises and is used repeatedly by 
multiple users, creating opportunities 
for viral interactions. Despite some 
declines in heroin production and 
export, Burma remains the world’s 
second-leading producer and the 
largest heroin exporter in Southeast 
Asia [29,30]. 
      TB.   South and Southeast Asia have 
the highest burden of TB worldwide: 
one in three cases of TB diagnosed 
worldwide is in this region [31]. 
Burma reports some 97,000 new 
cases diagnosed each year to WHO, 
which WHO has suggested may be 
underreporting the actual incidence 
[1,32–34]. Overall, approximately 40% 
of Burma’s population is estimated 
to be infected with TB [34]. The 
Ministry of Health has designated TB 
as a priority disease [18]. Nevertheless, 
Burma has been rated by WHO as 
moving far too slowly to adequately 
control TB—a problem identiﬁ  ed 
by WHO as far back as 1998 as being 
due to a lack of political will and 
commitment [32].
    The epidemic of TB in Burma is 
closely linked to HIV. WHO estimates 
that approximately 6.8% of patients 
with TB in Burma have HIV, while 
60%–80% of patients living with HIV 
also have TB—making TB the most 
common opportunistic infection 
in people living with HIV/AIDS 
[31,34,35] Burma has the highest 
mortality rate—i.e., 2.8 per 100,000—
among patients with TB who are 
coinfected with HIV in Southeast Asia 
[32]. 
    With the introduction of WHO’s 
Directly Observed Therapy, Short-
Course (DOTS) program in Burma 
in 1997, the government reports that 
case detection rates have improved 
[32]. In 2005 the country claims to 
have 100% DOTS coverage among its 
324 townships and a treatment success 
rate of 81%—just below WHO’s goal of 
85% for 2005 [19,31,36]. But program 
data suggest that this optimistic 
scenario may not be accurate. A 
2005 WHO report noted that “the 
National TB Program (NTP) budget 
was around US$3 million in 2002, but 
DOI: 10.1371/journal.pmed.0030393.g002
  Figure 2.   Malaria Risk Areas in Burma 
    The areas at highest risk are overwhelmingly 
along the frontiers, where civil conﬂ  ict is 
ongoing and widespread human rights abuses 
have been documented.
    Source: WHO Regional Ofﬁ  ce for South-East 
Asia [76] 
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a large funding gap meant that actual 
expenditures were only around US$1 
million, primarily for staff and ﬁ  rst-line 
drugs” [19]. It also noted a “…shortage 
of qualiﬁ  ed staff, especially junior 
laboratory technicians,” and that “…a 
quarter of all sanctioned posts in the 
NTP are vacant” [19]. 
    There is also microbiologic 
evidence—i.e., rising antibiotic 
resistance—that the TB control 
program in Burma is troubled. In the 
ﬁ  rst report on multidrug-resistant 
(MDR) TB in Burma, in 2000, 33.3% of 
isolates from patients newly diagnosed 
with pulmonary TB were resistant to 
at least one ﬁ  rst-line drug, and 2% of 
isolates were MDR TB [37]. In a 2005 
follow-up analysis by the same group, 
33.9% of TB isolates were resistant to 
any one of the four standard ﬁ  rst-line 
drugs, with the rate of MDR TB more 
than doubling to 4.2%; among patients 
who had received treatment in the 
past, this ﬁ  gure rose to 18.4% [38]. 
The authors found that a history of 
exposure to TB treatment for at least 
one month was associated with over 
3-fold odds of developing MDR TB. 
Average MDR rates in Southeast Asia 
are roughly 2.0%, so Burma’s ofﬁ  cial 
MDR-TB rates are more than double 
those of neighboring countries [39]. 
One report from the Thai side of the 
Thai–Burma border found that MDR 
TB accounted for 6.5% of TB isolates, 
compared with 0.9% for the rest of 
Thailand [40].
      Malaria.   Burmese ofﬁ  cial statistics 
reported to WHO show that malaria 
causes proportionately more mortality 
in Burma than in any other country 
in Southeast Asia [41]. Burma 
reported over 700,000 cases of 
clinically suspected malaria in 2004, 
of which almost 80% was Plasmodium 
falciparum, and consistently records 
the most malaria-related deaths of 
any country in the region [41–43]. 
This ﬁ  gure puts Burma’s reported 
malaria caseload at about 7.3% of 
the WHO regional disease burden, 
but responsible for 53.6% of malaria-
related deaths in the region—many 
of which occur in children under ﬁ  ve 
(Figure 1) [1,41,42].
    According to 2003 WHO data, the 
annualized country-wide incidence rate 
of malaria is approximately 3.6 cases 
per 1,000 population, (0.36%) per 
year [41]. The areas at greatest risk are 
the forested border areas of Burma, 
populated by ethnic-minority groups 
living in areas marked by civil conﬂ  ict 
(Figure 2). Over half of Burma’s cases 
of malaria are reported from just 
100 townships in these areas, which 
account for only 25% of the population 
(13.7 million people) [44]. In one 
study, the malaria-related morbidity 
was highest in the Chin and Karenni 
states, located on the Indian and Thai 
borders, respectively [45]. Kachin 
state on the Chinese border, another 
ethnic-minority region, had mortality 
rates for malaria almost ﬁ  ve times 
higher than the national average [46]. 
Among internally displaced persons in 
the conﬂ  ict zones of eastern Burma, 
malaria accounted for 45% of all adult 
and child deaths in 2003–2004 [47,48]. 
    Burma has also become an epicenter 
for drug-resistant   P. falciparum  , 
particularly along the frontiers of 
the country [45]. Chloroquine and 
sulfadoxine-pyrimethamine (SP), two 
former mainstays of malaria treatment, 
are too frequently ineffective if used 
alone, so they have been abandoned in 
favor of combination therapies in the 
region [45,49–51]. The Thai–Burma 
border has documented signiﬁ  cant 
levels of clinical treatment failure and 
in vitro resistance against quinine 
and meﬂ  oquine: between 1986 and 
1997, a 10-fold decrease in meﬂ  oquine 
sensitivity was noted, and the use of this 
drug alone is also no longer effective 
[45,50]. 
    MDR   P. falciparum   malaria, deﬁ  ned 
as malaria that is resistant to three 
or more drugs, is most problematic 
on the Thai–Burma border [45]. As 
a result, combination therapy with 
artesunate and high-dose meﬂ  oquine 
is now the recommended treatment for 
falciparum malaria. There are currently 
no other practical alternatives in this 
area to artemisinin compounds [45,52] 
    Several factors may hasten the spread 
of drug-resistant malaria, including 
incomplete or inappropriate use of 
antimalarials, program failure, and 
the sale and use of fake or expired 
antimalarials. There is little regulatory 
oversight of the importation and sale 
of antimalarials in Burma, and the 
proportion of fake drugs is high [53]. 
Dondorp et al. reported in 2004 that 
21% of artesunate tested in Burma 
contained no active ingredients [54].
    The more expensive artemesinin 
derivatives strain already scarce 
resources available for treatment of 
malaria, and many Burmese continue 
to purchase their medications over 
the counter and on the black market 
[44,45,52,54]. Counterfeit artesunate, 
containing little or no active 
compound, is now common in Burma, 
where over one-ﬁ  fth of drugs sampled 
in one analysis were fake [53–55]. 
    Other Diseases and Health Threats: 
Avian Flu
    Avian ﬂ  u is a regional and global 
concern. Given Burma’s poor health 
and laboratory infrastructure and the 
limits on access to Burma, the concern 
over Burma’s potential to aid in the 
evolution of avian ﬂ  u is prudent. 
 Table  2.  HIV Sentinel Surveillance Data from March–April, 2003, from the National AIDS Control Program of the Ministry of Health, 
Burma (Myanmar)    
Groups Number of 
Sites
Total N  Number of 
People HIV+ 
Percent HIV+ Median Minimum Maximum
Male attendees with STDs 29 2,713 163 6.01 6.00 0 21.00
Female attendees with STD 8 693 63 9.09 12.55 1.00 18.18
Sex workers 2 185 58 31.35 11.00 55.17
IDUs 6 243 92 37.86 48.10 23.00 77.78
Antenatal clinic attendees 29 5,654 93 1.64 1.00 0 7.50
Blood donors 2 5,596 69 1.23 1.05 1.38
New military  2 1,199 25 2.09 1.00 3.17
    Source: National AIDS Control Program of the Ministry of Health, Burma (Myanmar) [20]
  DOI:  10.1371/journal.pmed.0030393.t002 
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Burma’s ﬁ  rst report of the H5N1 virus 
describes emergence on March 8, 2006, 
on a farm in the Mandalay district, 
about 430 miles north of Rangoon 
[56].
    Some 112 birds died in the outbreak. 
Veterinary authorities in the country 
called for international assistance, but 
the state-run media did not notify the 
Burmese people of the threat until 
March 17, 2006, more than a week 
later [57]. Six days after junta ofﬁ  cials 
ﬁ  rst began to investigate bird deaths 
and three days after the Ministry of 
Livestock and Fisheries conﬁ  rmed the 
presence of H5N1, Burma’s state-run 
press was silent on the issue. By March 
18, 2006, more that 10,000 birds were 
reported to have died, and 41,000 birds 
culled [57]. 
    The main concern with the failure 
to inform the public about avian ﬂ  u 
is the risk of further unwitting spread 
(through continued transport and sale 
of animals, or through other exposures 
to animal waste). Such spread has 
subsequently been reported in Burma 
by the UN Food and Agriculture 
Organization (FAO), with over 100 
bird ﬂ  u outbreaks reported by FAO 
at an April 10, 2006, press conference 
in Bangkok [58]. He Changchui, 
the FAO representative for Asia-
Paciﬁ  c, stated that “the issue there 
is that awareness is rather poor. The 
information is not that comprehensive” 
[58]. Encouragingly, specimens from 
Mandalay were sent to Bangkok for 
conﬁ  rmatory testing, and the SPDC was 
reportedly cooperating with the FAO: 
they quarantined poultry farms around 
the initial outbreak, and they have 
shared samples from infected animals 
with Thailand and Australia [57]. The 
delay in alerting the Burmese people, 
however, appears to have undermined 
the effectiveness of the early response.
    Regional Issues and Security 
Threats
    How important are Burma’s ongoing 
epidemics of HIV/AIDS, TB, and 
malaria to the country’s neighbors? 
A driver of regional importance in 
HIV/AIDS has been the interaction 
between the spread of HIV and 
narcotics use and exports from 
Burma. Burma remains the world’s 
second-largest opium- and heroin-
producing state, and has dramatically 
increased its production and export of 
methamphetamine [29,59]. In Burma’s 
border regions with China and India, 
the epidemiologic impact of Burma’s 
HIV/AIDS epidemic has been driven 
on both sides of the country’s borders 
by spread related to illicit drug use 
[60]. A recent report also adds the 
Burma–Bangladesh border to those 
regions where heroin exports from 
Burma have led to increases in heroin 
use [61]. 
    Yunnan Province, in China’s 
southwest, is the area with the highest 
HIV prevalence in China. Epidemic 
spread in Yunnan began among IDUs 
in several districts on the Yunnan–
Burma border in the early 1990s 
[62]. The uptake of heroin use, and 
subsequent epidemics of IDU-related 
infections, including HIV and hepatitis 
C, are direct outcomes of Burma’s 
heroin exports to China [62,63]. 
    The National AIDS Control Program 
of India, in collaboration with the 
Avahan Program, has mapped the 
HIV prevalence rates among pregnant 
  Table 3.   HIV Seropositivity (%) by Sites, among Sentinel Populations, March–April, 2003    
Sites Male  Attendees 
with STDs
Female Attendees 
with STDs
Sex Workers IDUs Antenatal Clinic 
Attendees
Blood 
Donors
Military 
Recruits
Rangoon 15.0 15.0 11.0 33.33 2.0 1.05 1.00
Mandalay 7.55 18.18 55.17 53.57 0.50 1.38 3.17
Meiktila 21.0 2.50
Taungyi 11.0 1.00 23.00 1.00
Lashio 1.0 77.78 0.50
Tachilek 13.00 2.75
Muse 2.50 66.67 3.11
Dawei 7.00 3.00 0.50
Kawthaung 3.0 16.0 1.0
Myitkyeena 13.51 17.19 42.62 1.50
Bamaw 10.0 2.01
Mawlamyaing 0 0.53
Pathein 0 0
Bago 7.0 10.1 0
Pyay 14.0 5.0
Magway 6.0 1.5
Hpa-an 0.00 7.50
Sittwe 2.0 0.00
Monywa 0 2.0 1.0
Liokaw 0 0
Haka 2.17 0
Hintharta 0 2.0
Maubin 0 1.0
Myeik 4.0 2.0
Myingyan 6.0 0.50
Pakokku 4.0 3.5
Shwebo 9.0 2.0
Kyaington 8.0 2.0
Myawaddy 6.0 1.0
    Source: National AIDS Control Program of the Ministry of Health, Burma (Myanmar) [20]
  DOI:  10.1371/journal.pmed.0030393.t003 
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women across India’s HIV- surveillance-
reporting districts [64]. These data 
show high rates of infection in two 
of India’s most remote regions, the 
northeastern states of Manipur and 
Nagaland—both of which border 
Burma. Both states are on principal 
overland heroin-trafﬁ  cking routes out 
of Burma [60]. 
    The population exodus from Burma 
has made MDR TB an issue of regional 
concern [16]. Isolates collected from 
patients on the Thai side of the border 
who are Burmese migrants reveal that 
MDR TB now accounts for 6.5% of TB 
isolates, compared with the national 
average of 0.9% for the rest of Thailand 
[40]. In some Thai provinces bordering 
Burma, almost half of all patients with 
TB are not Thai, and cure rates among 
these individuals is low—25.8% in one 
analysis—threatening Thailand’s ability 
to control TB and raising costs [65,66]. 
    The large-scale migration of Burmese 
people across international borders 
has signiﬁ  cant regional malaria-control 
implications, especially for Thailand, 
where malaria incidence rates have 
been steadily declining. This declining 
trend is not seen in those provinces 
that share a border with Burma [67,68]. 
Of these, Tak Province, adjacent to 
Burma’s Karen state, has the highest 
numbers of cases of malaria, and in one 
study the prevalence of asymptomatic 
parasitemia in Tak migrants was over 20 
times that of the local Thai population 
(4.4% versus 0.2%) [69]. 
    MDR-malaria parasites are common 
along the Thai–Burma border [43]. A 
similar spillover effect has also been 
noted in India and China, where 
migration across porous borders 
threatens to undermine local malaria-
control efforts [69–73]. On India’s 
northeastern border with Burma, the 
risk of treatment failure decreases 
with increasing distance away from the 
border [73].
  Discussion  and  Conclusion
    Given the scale and scope of Burma’s 
health needs, are there policy options 
for health work in this current climate? 
Several options for working in Burma 
may have some utility: (1) cross-border 
approaches, (2) use of independent 
media for health education and 
information, and (3) expanded support 
through international organizations 
and NGOs (nongovernmental 
organizations). 
    One of our ﬁ  ndings was that much 
of the available data on HIV/AIDS, 
TB, and malaria come from border 
areas. Indeed, one might assume that 
the health threats themselves were 
most marked in the Thai–Burma 
border areas. However, at least some 
of the emphasis on data from this area 
is no doubt a result of the paucity of 
information from areas bordering 
India, Bangladesh, the Lao People’s 
Democratic Republic, and China. 
Cross-border efforts, where feasible, 
are likely to increase in importance in 
regard to the health of the Burmese 
people if SPDC restrictions continue to 
tighten.
    Many communities of internally 
displaced people on the Thai–Burma 
border rely on a network of mobile 
indigenous health workers, known 
collectively as “Backpack Health 
Worker Teams,” for basic health 
care. These communities have very 
poor access to health services and are 
considered inhabitants of “black zone,” 
or “conﬂ  ict” areas, by the SPDC. These 
health workers are indigenous, highly 
mobile, and have successfully navigated 
the ongoing conﬂ  ict to provide much-
needed care and information. 
    A number of other ethnic 
groups within Burma have health 
organizations that operate clinics and/
or mobile backpack teams (including 
the Arakanese, Chin, Kachin, Shan, 
Palaung, Karenni, and Mon) on all of 
Burma’s borders, with varying degrees 
of development. The Karen team, for 
example, runs more than 30 clinics, 
servicing a population of over 80,000; 
the Kachin, more than 60 clinics, 
servicing a population of 98,000 [74]. 
With international support, these 
ethnic groups could have the potential 
to reach a substantial proportion of the 
population with two key characteristics: 
(1) the highest disease burden and 
(2) the highest potential to transmit 
infection to neighboring countries. 
    The new government guidelines 
for the provision of humanitarian 
assistance put forth by the Ministry 
of National Planning and Economic 
Development in early 2006, if 
enforced, is likely to markedly diminish 
independent capacity to respond to 
health threats in Burma. Nevertheless, 
a number of organizations and NGOs 
will continue their activities in Burma, 
as well as continue to provide needed 
services. While a range of donors are 
engaged in efforts to counter the 
funding losses incurred by the pullout 
of the Global Fund, the new restrictions 
are more explicitly supportive of 
junta control of activities, stafﬁ  ng, 
site visits, procurement, and the like. 
The fundamental dilemma of how 
best to respond to health threats and 
provide humanitarian assistance while 
the SPDC further restricts access to 
Burma’s neediest has worsened in 2006. 
    Health-related programs such as 
Population Services International, 
Médecins Sans Frontières Netherlands, 
and numerous others that are currently 
functioning in Burma are likely to 
continue. But from a public health 
perspective, much more fundamental 
and widespread change will be 
required to actually meet the scale 
and scope of Burma’s HIV/AIDS, TB, 
and malaria epidemics, increasing 
malnutrition, and other health threats. 
While such reform in Burma has been 
painfully slow, disease spread can be 
markedly rapid. Perhaps the concerns 
over emergent avian ﬂ  u will have more 
regional impact than the tragedies of 
HIV/AIDS, TB, and malaria in Burma 
have had to date.  
    A longer version of this report is available at 
http:⁄⁄www.jhsph.edu/humanrights/research.
    The Chinese- and Burmese-language versions 
of the executive summary are available at 
http:⁄⁄www.soros.org/initiatives/bpsai/
articles_publications/publications/
respondingtoaids_20060330. 
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